5th Aug 2019 11:45
(Alliance News) - Evgen Pharma PLC said Monday that it backs the new research collaboration between King's College London and the British Heart Foundation.
The collaboration is researching how SFX-01 - Evgen's breast cancer drug - can provide neurovascular protection against strokes. The collaboration is mainly funded by the British Heart Foundation as a PhD studentship at King's College London.
This work will build on the existing collaboration between Evgen and King's, which has demonstrated vascular protection in murine models of ischaemic stroke, the most common type of stroke.
Evgen will supply the drug to the project and has the right to negotiate a licence over any resultant intellectual property.
"We are delighted to be collaborating again with Evgen Pharma and believe this project will build on our existing collaboration which showed great promise for SFX-01 in both stroke and potentially wider neuropsychiatric complications,'' commented Professor of Vascular Physiology at King's College London and supervisor for the project Giovanni Mann.
''We welcome the opportunity to continue working with Professor Mann in developing the opportunities for SFX-01 in neurology. Meanwhile, we look forward to our Phase IIb clinical data from SFX-01 in subarachnoid stroke which we will announce later this year." Evgen Chief Executive Steve Franklin commented
Shares in Evgen were untraded on Monday in London, last quoted at 17.75 pence each.
Related Shares:
EVG.L